Literature DB >> 12902353

Characterization of 2'-fluoro-RNA aptamers that bind preferentially to disease-associated conformations of prion protein and inhibit conversion.

Alexandre Rhie1, Louise Kirby, Natalie Sayer, Rosanna Wellesley, Petra Disterer, Ian Sylvester, Andrew Gill, James Hope, William James, Abdessamad Tahiri-Alaoui.   

Abstract

We have isolated artificial ligands or aptamers for infectious prions in order to investigate conformational aspects of prion pathogenesis. The aptamers are 2'-fluoro-modified RNA produced by in vitro selection from a large, randomized library. One of these ligands (aptamer SAF-93) had more than 10-fold higher affinity for PrPSc than for recombinant PrPC and inhibited the accumulation of PrPres in near physiological cell-free conversion assay. To understand the molecular basis of these properties and to distinguish specific from non-specific aptamer-PrP interactions, we studied deletion mutants of bovine PrP in denatured, alpha-helix-rich and beta-sheet-rich forms. We provide evidence that, like scrapie-associated fibrils (SAF), the beta-oligomer of PrP bound to SAF-93 with at least 10-fold higher affinity than did the alpha-form. This differential affinity could be explained by the existence of two binding sites within the PrP molecule. Site 1 lies within residues 23-110 in the unstructured N terminus and is a nonspecific RNA binding site found in all forms of PrP. The region between residue 90 and 110 forms a hinge region that is occluded in the alpha-rich form of PrP but becomes exposed in the denatured form of PrP. Site 2 lies in the region C-terminal of residue 110. This site is beta-sheet conformation-specific and is not recognized by control RNAs. Taken together, these data provide for the first time a specific ligand for a disease conformation-associated site in a region of PrP critical for conformational conversion. This aptamer could provide tools for the further analysis of the processes of PrP misfolding during prion disease and leads for the development of diagnostic and therapeutic approaches to TSEs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12902353     DOI: 10.1074/jbc.M305297200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

1.  Selection of aptamers for amyloid beta-protein, the causative agent of Alzheimer's disease.

Authors:  Farid Rahimi; Gal Bitan
Journal:  J Vis Exp       Date:  2010-05-13       Impact factor: 1.355

2.  Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease.

Authors:  Rajeev K Chaudhary; Kinjal A Patel; Milan K Patel; Radha H Joshi; Ipsita Roy
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

3.  Rapid formation of amyloid from alpha-monomeric recombinant human PrP in vitro.

Authors:  Abdessamad Tahiri-Alaoui; William James
Journal:  Protein Sci       Date:  2005-03-01       Impact factor: 6.725

4.  A mathematical analysis of SELEX.

Authors:  Howard A Levine; Marit Nilsen-Hamilton
Journal:  Comput Biol Chem       Date:  2007-01-10       Impact factor: 2.877

5.  Immunodetection of disease-associated mutant PrP, which accelerates disease in GSS transgenic mice.

Authors:  Karah E Nazor; Franziska Kuhn; Tanya Seward; Mike Green; Daniel Zwald; Mario Pürro; Jaqueline Schmid; Karin Biffiger; Aisling M Power; Bruno Oesch; Alex J Raeber; Glenn C Telling
Journal:  EMBO J       Date:  2005-06-16       Impact factor: 11.598

6.  Anti-bovine prion protein RNA aptamer containing tandem GGA repeat interacts both with recombinant bovine prion protein and its beta isoform with high affinity.

Authors:  Kazuyoshi Murakami; Fumiko Nishikawa; Ken Noda; Takashi Yokoyama; Satoshi Nishikawa
Journal:  Prion       Date:  2008-04-17       Impact factor: 3.931

7.  A computationally designed DNA aptamer template with specific binding to phosphatidylserine.

Authors:  Md Ashrafuzzaman; Chih-Yuan Tseng; Janice Kapty; John R Mercer; Jack A Tuszynski
Journal:  Nucleic Acid Ther       Date:  2013-11-26       Impact factor: 5.486

Review 8.  Pathological implications of nucleic acid interactions with proteins associated with neurodegenerative diseases.

Authors:  Yraima Cordeiro; Bruno Macedo; Jerson L Silva; Mariana P B Gomes
Journal:  Biophys Rev       Date:  2014-01-09

Review 9.  Aptamer and its applications in neurodegenerative diseases.

Authors:  Jing Qu; Shuqing Yu; Yuan Zheng; Yan Zheng; Hui Yang; Jianliang Zhang
Journal:  Cell Mol Life Sci       Date:  2016-08-25       Impact factor: 9.261

10.  RNA aptamers generated against oligomeric Abeta40 recognize common amyloid aptatopes with low specificity but high sensitivity.

Authors:  Farid Rahimi; Kazuma Murakami; Jamie L Summers; Chi-Hong B Chen; Gal Bitan
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.